Equities research analysts predict that Viveve Medical Inc (NASDAQ:VIVE) will announce sales of $3.37 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Viveve Medical’s earnings, with estimates ranging from $2.90 million to $4.15 million. Viveve Medical posted sales of $3.70 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 8.9%. The business is scheduled to issue its next quarterly earnings results on Thursday, March 14th.
On average, analysts expect that Viveve Medical will report full-year sales of $19.48 million for the current financial year, with estimates ranging from $19.00 million to $20.05 million. For the next year, analysts forecast that the business will report sales of $28.60 million, with estimates ranging from $24.65 million to $34.07 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Viveve Medical.
VIVE has been the subject of several analyst reports. Raymond James lowered their price target on shares of Viveve Medical from $4.50 to $3.00 and set an “outperform” rating for the company in a research report on Wednesday, December 12th. Craig Hallum set a $1.00 price target on shares of Viveve Medical and gave the stock a “hold” rating in a research report on Friday, January 18th. Maxim Group reiterated a “buy” rating on shares of Viveve Medical in a research report on Thursday, January 17th. Finally, Mizuho reiterated a “buy” rating and set a $4.00 price target on shares of Viveve Medical in a research report on Friday, March 15th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $4.00.
Several large investors have recently modified their holdings of VIVE. Nantahala Capital Management LLC grew its position in shares of Viveve Medical by 66.7% during the 4th quarter. Nantahala Capital Management LLC now owns 6,581,465 shares of the company’s stock worth $6,911,000 after buying an additional 2,633,333 shares during the period. RTW Investments LP grew its position in shares of Viveve Medical by 42.4% during the 4th quarter. RTW Investments LP now owns 4,480,565 shares of the company’s stock worth $4,705,000 after buying an additional 1,333,333 shares during the period. Bank of New York Mellon Corp grew its position in shares of Viveve Medical by 266.6% during the 4th quarter. Bank of New York Mellon Corp now owns 45,223 shares of the company’s stock worth $47,000 after buying an additional 32,888 shares during the period. Sargent Investment Group LLC acquired a new stake in shares of Viveve Medical during the 4th quarter worth approximately $32,000. Finally, Geode Capital Management LLC grew its holdings in Viveve Medical by 13.6% during the fourth quarter. Geode Capital Management LLC now owns 216,566 shares of the company’s stock valued at $227,000 after purchasing an additional 25,975 shares during the period. Institutional investors own 89.64% of the company’s stock.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.